Synthetic Biologics CEO On Pipeline Advances And The Microbiome
Scrip senior editor Lucie Ellis speaks to Jeff Riley, president and CEO of Synthetic Biologics, on the sidelines of the recent BIO-Europe partnering conference in Berlin about how the company is harnessing the microbiome to develop two late-stage therapeutics.
You may also be interested in...
Company believes there is a path forward for developing ribaxamase in Phase III, based on discussions with the FDA, but deaths in Phase II meant loss of breakthrough designation.
Events are moving fast in the microbiome field. The sector is expecting results from numerous initial clinical studies during 2018, from across a spectrum of approaches and mechanisms of action, which could lead to new rounds of financings and M&A activity.
Anker Lundemose, CEO of UK-based Mission Therapeutics, outlines the company's emerging DUBs drug discovery platform on the sidelines of the recent BIO-Europe partnering conference in Berlin.